Нефротоксичность комбинированной лекарственной терапии метастатического рака почки
https://doi.org/10.17650/1726-9776-2023-19-3-153-162
Аннотация
Данный обзор литературы посвящен снижению функции почек при почечно-клеточном раке. По данным международных исследований, ряд пациентов на момент дебюта заболевания уже имеют хроническую болезнь почек. Хирургическое лечение приводит к уменьшению общего количества функционирующих нефронов. Лекарственная терапия вызывает ряд побочных явлений, в том числе нефротоксичность. В обзоре освещена проблема применения комбинированных режимов у пациентов с единственной почкой.
Ключевые слова
почечно-клеточный рак,
иммунотерапия,
таргетная терапия,
хроническая болезнь почек,
острое повреждение почек
При поддержке: Авторы выражают благодарность д.м.н. Е.В. Шутову за помощь в подготовке статьи, научную консультацию и написание разделов, посвященных патогенезу хронической болезни почек на фоне лекарственной терапии.
Об авторах
К. С. Титов
ГБУЗ г. Москвы «Городская клиническая больница им. С.П. Боткина Департамента здравоохранения г. Москвы»; ФГАОУ ВО «Российский университет дружбы народов им. Патриса Лумумбы»
Россия
Конфликт интересов:
Россия
125284 Москва, 2‑й Боткинский пр‑д, 5; 117198 Москва, ул. Миклухо‑Маклая, 6
Конфликт интересов:
Нет
Е. В. Шутов
ГБУЗ г. Москвы «Городская клиническая больница им. С.П. Боткина Департамента здравоохранения г. Москвы»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России
Россия
Конфликт интересов:
Россия
125284 Москва, 2‑й Боткинский пр‑д, 5; 125993 Москва, ул. Баррикадная, 2/1, стр. 1
Конфликт интересов:
Нет
А. А. Алимов
ГБУЗ г. Москвы «Городская клиническая больница им. С.П. Боткина Департамента здравоохранения г. Москвы»; ФГАОУ ВО «Российский университет дружбы народов им. Патриса Лумумбы»
Россия
Конфликт интересов:
Россия
Алимов Артемий Андреевич - аспирант кафедры онкологии и рентгенорадиологии им. В.П. Харченко МИ РУДН; врач-онколог ЦАОП ГКБ им. С.П. Боткина.
125284 Москва, 2‑й Боткинский пр‑д, 5; 117198 Москва, ул. Миклухо‑Маклая, 6
Конфликт интересов:
Нет
С. С. Лебедев
ГБУЗ г. Москвы «Городская клиническая больница им. С.П. Боткина Департамента здравоохранения г. Москвы»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России
Россия
Конфликт интересов:
Россия
125284 Москва, 2‑й Боткинский пр‑д, 5; 125993 Москва, ул. Баррикадная, 2/1, стр. 1
Конфликт интересов:
Нет
А. А. Киричек
ГБУЗ г. Москвы «Городская клиническая больница им. С.П. Боткина Департамента здравоохранения г. Москвы»
Россия
Конфликт интересов:
Россия
125284 Москва, 2‑й Боткинский пр‑д, 5
Конфликт интересов:
Нет
Г. М. Запиров
ФГАОУ ВО «Российский университет дружбы народов им. Патриса Лумумбы»
Россия
Конфликт интересов:
Россия
117198 Москва, ул. Миклухо‑Маклая, 6
Конфликт интересов:
Нет
Список литературы
1. World Health Organization. The Global Cancer Observatory. Available at: https://gco.iarc.fr.
2. Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. 252 с.
3. SEER Explorer. Available at: https://seer.cancer.gov/explorer/index.html (accessed March 2, 2020).
4. Heng D.Y., Wells J.C., Rini B. et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2014;66(4):704-10. DOI: 10.1016/j.eururo.2014.05.034
5. Mejean A., Ravaud A., Thezenas S. et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 2018;379(5):417-27. DOI: 10.1056/NEJMoa1803675
6. Bex A., Mulders P., Jewett M. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME Randomized Clinical Trial. JAMA Oncol 2019;5(2):164-70. DOI: 10.1001/jamaoncol.2018.5543
7. Dey S., Hamilton Z., Noyes S.L. et al. Chronic kidney disease is more common in locally advanced renal cell carcinoma. Urology 2017;105:101-7. DOI: 10.1016/j.urology.2017.03.033
8. Woldu S.L., Weinberg A.C., Roy Choudhury A. et al. Renal insufficiency is associated with an increased risk of papillary renal cell carcinoma histology. Int Urol Nephrol 2014;46(11):2127-32. DOI: 10.1007/s11255-014-0780-4
9. Ellis R.J., White V.M., Bolton D.M. et al. Tumor size and postoperative kidney function following radical nephrectomy. Clin Epidemiol 2019;11:333-48. DOI: 10.2147/CLEP.S197968
10. Yang Y., Kozel Z., Sharma P. et al. Identifying patients with CKD risk at the time of nephrectomy: when to initiate nephrology consult. J Onco-Nephrol 2021;5(2):105-13.
11. Saly D.L., Eswarappa M.S., Street S.E., Deshpande P. Renal cell cancer and chronic kidney disease. Adv Chronic Kidney Dis 2021;28(5):460-8. DOI: 10.1053/j.ackd.2021.10.008
12. Escudier B., Porta C., Schmidinger M. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up dagger. Ann Oncol 2019;30(5):706-20.
13. Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium. J Clin Oncol 2020;38(6_suppl):642-2. DOI: 10.1200/JCO.2020.38.6_suppl.642
14. Lane B.R., Babineau D.C., Poggio E.D. et al. Factors predicting renal functional outcome after partial nephrectomy. J Urol 2008;180(6):2363-8. DOI: 10.1016/j.juro.2008.08.036
15. Clark M.A., Shikanov S., Raman J.D. et al. Chronic kidney disease before and after partial nephrectomy. J Urol 2011;185(1):43-8. DOI: 10.1016/j.juro.2010.09.019
16. Cho A., Lee J.E., Kwon G.Y. et al. Post-operative acute kidney injury in patients with renal cell carcinoma is a potent risk factor for new- onset chronic kidney disease after radical nephrectomy. Nephrol Dial Transpl 2011;26(11):3496-501. DOI: 10.1093/ndt/gfr094
17. Bravi C.A., Vertosick E., Benfante N. et al. Impact of acute kidney injury and its duration on long-term renal function after partial nephrectomy. Eur Urol 2019;76(3):398-403. DOI: 10.1016/j.eururo.2019.04.040
18. Manohar S., Kompotiatis P., Thongprayoon C. et al. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. Nephrol Dial Transpl 2019;34(1):108-17. DOI: 10.1093/ndt/gfy105
19. Cortazar F.B., Marrone K.A., Troxell M.L. et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 2016;90(3):638-47. DOI: 10.1016/j.kint.2016.04.008
20. Kitchlu A., Jhaveri K.D., Sprangers B. et al. Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review. Clin Kidney J 2021;14(9):2012-22. DOI: 10.1093/ckj/sfab090
21. Murakami N., Mulvaney P., Danesh M. et al. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int 2021;100(1):196-205. DOI: 10.1016/j.kint.2020.12.015
22. Akturk H.K., Alkanani A., Zhao Z. et al. PD-1 inhibitor immune-related adverse events in patients with pre-existing endocrine autoimmunity. J Clin Endocrinol Metab 2018;103(10):3589-92. DOI: 10.1210/jc.2018-01430
23. Ansari J., Ali M., Farrag A. et al. Efficacy of nivolumab in a patient with metastatic renal cell carcinoma and end-stage renal disease on dialysis: case report and literature review. Case Reports Immunol 2018;2018:1623957. DOI: 10.1155/2018/1623957
24. Cheun H., Kim M., Lee H. et al. Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review. Invest New Drugs 2019;37(3):579-83. DOI: 10.1007/s10637-018-0673-y
25. Fernandez-Diaz A.B., Cunquero-Tomas A.J., Garcia-Medina A. et al. Are patients in haemodialysis good candidates for immunotherapy treatment? Melanjma Res 2019;29(5):553-5. DOI: 10.1097/CMR.0000000000000616
26. Ito A., Hisano M., Takahashi M. et al. Complete response to nivolumab for metastatic renal cell carcinoma on hemodialysis patients; a case report. Urol Case Rep 2019;28:101048. DOI: 10.1016/j.eucr.2019.101048
27. Morinaga R., Kawahara T., Miyoshi Y. et al. Longer control of nivolumab in metastatic renal cell carcinoma patients with endstage kidney disease on dialysis. Case Rep Oncol 2019;12(2):608-12. DOI: 10.1159/000501768
28. Parisi A., Cortellini A., Cannita K. et al. Safe administration of anti-PD-L1 atezolizumab in a patient with metastatic urothelial cell carcinoma and end-stage renal disease on dialysis. Case Rep Oncol Med 2019;2019:3452762. DOI: 10.1155/2019/3452762
29. Tachibana H., Kondo T., Ishihara H. et al. Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma and end-stage renal disease at 2 centers. Clin Genitourin Cancer 2019;17(4):e772-8. DOI: 10.1016/j.clgc.2019.04.004
30. Vitale M.G., Baldessari C., Milella M. et al. Immunotherapy in dialysis-dependent cancer patients: our experience in patients with metastatic renal cell carcinoma and a review of the literature. Clin Genitourin Cancer 2019;17(5):e903-8. DOI: 10.1016/j.clgc.2019.06.009
31. Hirsch J.S., Wanchoo R., Ng J.H. et al. Use of immune checkpoint inhibitors in end stage kidney disease patients, single center experience and review of the literature. Kidney360 2020;1(5):399-402. DOI: 10.34067/KID.0000422020
32. Jain J., Stein J., Garje R. Evaluation of checkpoint inhibitors in cancer patients with end-stage renal disease on hemodialysis: case series and review of the literature. J Immunother 2020;43(8):244-9. DOI: 10.1097/CJI.0000000000000327
33. Osman-Garda I., Congregado-Ruiz C.B., Lendmez-Cano G. et al. Outcomes and safety of biweekly and monthly nivolumab in patients with metastatic renal cell carcinoma and dialysis: three case reports and literature review. Urol Int 2020;104(3-4):323-6. DOI: 10.1159/000504515
34. Mejia C.D., Frank A.M., Singh P., Yadav A. Immune check point inhibitor therapy-associated graft intolerance syndrome in a failed kidney transplant recipient. Am J Transplant 2021;21(3):1322-5. DOI: 10.1111/ajt.16326
35. Strohbehn I.A., Lee M., Seethapathy H. et al. Safety and efficacy of immune checkpoint inhibitors in patients on dialysis: a retrospective case series. Am J Kidney Dis 2020;76(2):299-302. DOI: 10.1053/j.ajkd.2020.02.451
36. Duni A., Kitsos A., Liapis G. et al. Acute kidney transplant rejection after administration of nivolumab in a dialysis patient with a failed graft. Kidney Int Rep 2021;6(5):1459-63. DOI: 10.1016/j.ekir.2021.02.039
37. Tan B., Baxter M., Casasola R. Acute renal transplant rejection following nivolumab therapy for metastatic melanoma. BMJ Case Rep 2021;14(2):e238037. DOI: 10.1136/bcr-2020-238037
38. Izzedine H., Gueutin V., Gharbi C. et al. Kidney injuries related to ipilimumab. Invest New Drugs 2014;32(4):769-73. DOI: 10.1007/s10637-014-0092-7
39. Abdel-Wahab N., Shah M., Suarez-Almazor M.E. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One 2016;11(7):e0160221. DOI: 10.1371/journal.pone.0160221
40. Fadel F., El Karoui K., Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 2009;361(2):211-2. DOI: 10.1056/NEJMc0904283
41. Richards D.M., Kyewski B., Feuerer M. Re-examining the nature and function of self-reactive T cells. Trends Immunol 2016;37(2):114-25. DOI: 10.1016/j.it.2015.12.005
42. Koda R., Watanabe H., Tsuchida M. et al. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report. BMC Nephrol 2018;19(1):48. DOI: 10.1186/s12882-018-0848-y
43. Perazella M.A., Shirali A.C. Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do? Kidney Int 2020;97(1):62-74. DOI: 10.1016/j.kint.2019.07.022
44. Cortazar F.B., Kibbelaar Z.A., Glezerman I.G. et al. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol 2020;31(2):435-46. DOI: 10.1681/ASN.2019070676
45. Gigante M., Blasi A., Loverre A. et al. Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine. Mol Immunol 2009;46(5):893-901. DOI: 10.1016/j.molimm.2008.09.015
46. Kitchlu A., Jhaveri K.D., Wadhwani S. et al. A systematic review of immune checkpoint inhibitor-associated glomerular disease. Kidney Int Rep 2021;6(1):66-77. DOI: 10.1016/j.ekir.2020.10.002
47. Mamlouk O., Selamet U., Machado S. et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer 2019;7(1):2. DOI: 10.1186/s40425-018-0478-8
48. Rini B.I., Escudier B., Tomczak P. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378(9807):1931-9. DOI: 10.1016/S0140-6736(11)61613-9
49. Motzer R.J., Hutson T.E., Cella D. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369(8):722-31. DOI: 10.1056/NEJMoa1303989
50. Choueiri T.K., Hessel C., Halabi S. et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer 2018;94:115-25. DOI: 10.1016/j.ejca.2018.02.012
51. Rixe O., Bukowski R.M., Michaelson M.D. et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007;8(11):975-84. DOI: 10.1016/S1470-2045(07)70285-1
52. Motzer R.J., Penkov K., Haanen J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1103-15. DOI: 10.1056/NEJMoa1816047
53. Powles T., Plimack E.R., Soulieres D. et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol 2020;21(12):1563-73. DOI: 10.1016/S1470-2045(20)30436-8
54. Mielczarek L., Brodziak A., Sobczuk P. et al. Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function. Cancer Chemother Pharmacol 2021;87(6):723-42. DOI: 10.1007/s00280-021-04260-y
55. Amin A., Plimack E.R., Ernstoff M.S. et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother Cancer 2018;6(1):109.
56. Motzer R., Alekseev B., Rha S.Y. et al. CLEAR Trial Investigators. Lenvatinib plus Pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384(14):1289-300. DOI: 10.1056/NEJMoa2035716
57. Kappers M.H.W., van Esch J.H.M., Sluiter W. et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 2010;56(4):675-81. DOI: 10.1161/HYPERTENSIONAHA.109.149690
58. Hayman S.R., Leung N., Grande J.P., Garovic V.D. VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep 2012;14(4):285-94. DOI: 10.1007/s11912-012-0242-z
59. Usui J., Glezerman I.G., Salvatore S.P. et al. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. Hum. Pathol. 2014;45(9):1918-27. DOI: 10.1016/j.humpath.2014.05.015
60. Stylianou K., Lioudaki E., Papadimitraki E. et al. Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration. Nephrol Dial Transplant 2011;26(5):1742-5. DOI: 10.1093/ndt/gfr093
61. Rolleman E.J., Weening J., Betjes M.G. Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma. Nephrol Dial Transplant 2009;24(6):2002-3. DOI: 10.1093/ndt/gfp140
62. Winn S.K., Ellis S., Savage P. et al. Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect? Nephrol Dial Transplant 2009;24(2):673-5. DOI: 10.1093/ndt/gfn625
63. Eremina V., Sood M., Haigh J. et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Investig. 2003;111(5):707-16. DOI: 10.1172/JCI17423.
64. Sorich M.J., Rowland A., Kichenadasse G. et al. Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data. Br J Cancer 2016;114(12):1313-7. DOI: 10.1038/bjc.2016.147
65. Czarnecka A.M., Sobczuk P., Korniluk J. et al. Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma. Future Oncol 2017;13(1):31-49. DOI: 10.2217/fon-2016-0355
66. Paluri R.K., Sonpavde G., Morgan C. et al. Renal toxicity with mammalian target of rapamycin inhibitors: a meta-analysis of randomized clinical trials. Oncol Rev 2019;13(2):455. DOI: 10.4081/oncol.2019.455
67. Bertoni E., Bruschi M., Candiano G. et al. Posttransplant proteinuria associated with everolimus. Transplant Proc 2009;41(4):1216-7. DOI: 10.1016/j.transproceed.2009.03.093
68. Nakagawa S., Nishihara K., Inui K., Masuda S. Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury. Eur J Pharmacol 2012;696(1-3):143-54. DOI: 10.1016/j.ejphar.2012.09.010
69. Izzedine H., Escudier B., Rouvier P. et al. Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven. Ann Oncol 2013;24(9):2421-5. DOI: 10.1093/annonc/mdt233
Рецензия
Для цитирования:
Титов К.С., Шутов Е.В., Алимов А.А., Лебедев С.С., Киричек А.А., Запиров Г.М. Нефротоксичность комбинированной лекарственной терапии метастатического рака почки. Онкоурология. 2023;19(3):153-162. https://doi.org/10.17650/1726-9776-2023-19-3-153-162
For citation:
Titov K.S., Shutov E.V., Alimov A.A., Lebedev S.S., Kirichek A.A., Zapirov G.M. Nephrotoxicity of combination drug therapy in metastatic renal cancer. Cancer Urology. 2023;19(3):153-162. (In Russ.) https://doi.org/10.17650/1726-9776-2023-19-3-153-162
Просмотров: 38
Послать статью по эл. почте 
